Welcome to our dedicated page for Nervgen Pharma news (Ticker: NGENF), a resource for investors and traders seeking the latest updates and insights on Nervgen Pharma stock.
NervGen Pharma Corp. (NGENF) generates news primarily as a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Newsflow around NervGen often centers on clinical data from its Phase 1b/2a CONNECT SCI Study of its lead candidate NVG-291, regulatory interactions, financing activities, and capital markets developments.
Investors following NGENF news can expect detailed updates on NVG-291’s clinical progress, including topline and expanded data from the chronic cohort of the CONNECT SCI Study and ongoing enrollment in the subacute cohort. Company announcements have highlighted durable improvements in function, independence, and quality of life in individuals with chronic SCI, supported by neurophysiological measures such as changes in corticospinal and reticulospinal signaling. These releases provide insight into how NervGen interprets the efficacy profile and potential impact of NVG-291.
NervGen’s news also covers regulatory milestones, such as FDA Type C meetings and planned End-of-Phase 2 discussions, as well as designations like Fast Track from the FDA and Orphan Drug status from the EMA for spinal cord injury. Capital markets and corporate updates, including non-brokered private placements, at-the-market equity program activity, and the company’s approval for listing on Nasdaq under the symbol NGEN, are additional recurring themes.
Preclinical research updates, particularly Department of Defense–sponsored studies of NVG-291-R in models of traumatic hearing loss and peripheral nerve injury, further contribute to the news stream by illustrating the broader therapeutic potential of NervGen’s technology. For readers tracking NGENF, this news page offers a centralized view of clinical, regulatory, financing, and strategic developments as the company advances its neuroreparative pipeline.
NervGen (NASDAQ:NGEN) will present clinical data from the Phase 1b/2a CONNECT SCI study at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium in Washington, DC, Feb 15–17, 2026.
Adam Rogers, MD, CEO, will present on Sunday, Feb 15, 2026, 4:15–5:00 pm ET, in a session titled "Emerging Therapies with Challenges and Opportunities for the Future," discussing durable functional, independence, and quality-of-life improvements observed in chronic spinal cord injury.
NervGen (TSXV:NGEN; NASDAQ:NGEN) appointed Adam Rogers, MD, as President and Chief Executive Officer effective February 9, 2026. The Board cited his interim leadership, including the Company’s recent Nasdaq listing, and his physician-executive experience advancing NVG-291 toward late-stage development.
The company granted 717,891 stock options with a four-year vesting schedule and specified exercise prices and terms.
NervGen (NASDAQ:NGEN) will ring the Nasdaq closing bell on January 22, 2026 in New York City to mark its recent Nasdaq listing. Adam Rogers, MD, Chairman and Interim CEO, will be joined by management, board members, advisors and guests. The ceremony broadcast begins at 3:45 pm ET and will be livestreamed from the Nasdaq MarketSite Tower and available on Nasdaq’s X and Facebook pages. The event highlights NervGen’s focus on developing neuroreparative therapeutics for spinal cord injury.
NervGen Pharma (NASDAQ:NGEN) announced its common shares began trading on Nasdaq on January 8, 2026. The company is a clinical-stage biopharmaceutical developer of neuroreparative therapeutics, advancing NVG-291 for spinal cord injury (SCI).
Recent expanded Phase 1b/2a CONNECT SCI data (announced Nov 24, 2025) showed statistically significant improvements in upper-limb corticospinal signaling and reductions in hyperactive reticulospinal signaling, with reported durable functional and quality-of-life gains in chronic SCI. NervGen plans an FDA End-of-Phase 2 meeting in early 2026 to align on development and registration pathways.
NervGen Pharma (OTCQB:NGENF) filed a Form F-10 registration statement with the U.S. Securities and Exchange Commission on December 17, 2025 under the Multijurisdictional Disclosure System (MJDS).
The Registration Statement is not yet effective; no securities may be sold or offers accepted until it becomes effective. Management said the filing is intended to provide flexibility to pursue strategic initiatives aligned with the company’s growth strategy.
Investors can view the filing on EDGAR at www.sec.gov or request a copy from the company at 112-970 Burrard Street, Unit 1290, Vancouver, BC V6Z 2R4.
NervGen Pharma (OTCQB:NGENF) intends to amend 5,075,000 common share purchase warrants issued July 13, 2022. The proposed amendment converts the exercise price denomination from US$1.75 to the Canadian equivalent of C$2.44 to align with the company's functional currency and simplify accounting.
All other warrant terms remain unchanged. The amended terms are subject to acceptance by the TSX Venture Exchange.
NervGen Pharma (OTCQB:NGENF) reported third-quarter 2025 results and business updates highlighting expanded CONNECT SCI Study data, regulatory engagement, financing and pipeline progress. Expanded data showed durable, clinically meaningful improvements at Week 16: a 2.6-fold greater mean GRASSP Total Score and 3.7-fold greater GRASSP Quantitative Prehension versus placebo, higher patient-reported global improvement (75% vs 33%), and gains in bladder control and reduced spasticity. The FDA confirmed multiple regulatory pathways and an End-of-Phase 2 meeting expected in early 2026. On Nov 19, 2025, the company completed a US$10.05M private placement. Cash and investments were $11.4M at Sept 30, 2025.
NervGen (OTCQB:NGENF) reported expanded 16-week CONNECT SCI data showing durable, post-treatment improvements in function, independence, and quality of life in people with chronic spinal cord injury.
Key findings: NVG-291 participants (n=20 trial; avg. 3.5 years post-injury) had a 2.6-fold greater mean GRASSP total score improvement and 3.7-fold greater GRASSP quantitative prehension improvement versus placebo at Week 16; participant interviews up to 364 days reported sustained benefits including bladder control and reduced spasticity.
Neurophysiology: significant reductions in hyperactive reticulospinal signaling (leg 142%, p=0.0062; hand 48%, p=0.0280) and a correlation with strengthened corticospinal signaling (R=-0.794, p=0.006). FDA Type C meeting confirmed multiple regulatory pathways; an End-of-Phase 2 meeting is anticipated in early 2026.
NervGen (OTCQB:NGENF) announced a non-brokered private placement to raise up to US$10.05 million via issuance of up to 4,785,715 units at US$2.10 per unit. Each Unit includes one common share and one-half warrant; each whole warrant is exercisable at US$2.65 for 36 months.
Proceeds are intended to advance the company’s clinical development of NVG-291 and support an anticipated Nasdaq listing. Related parties, including officers and directors, are expected to participate. Closing is subject to TSXV approval and is expected on or about November 19, 2025. Securities will be subject to a four-month-plus-one-day hold.
NervGen Pharma (OTCQB: NGENF) announced groundbreaking Phase 1b/2a topline results for NVG-291 in chronic spinal cord injury treatment. The study demonstrated unprecedented improvements in corticospinal connectivity and functional gains, marking a historic breakthrough in SCI treatment.
Key findings include a 10.2-fold improvement in hand connectivity versus placebo and significant functional improvements in hand use. The treatment was generally safe and well-tolerated. The company reported $15.7 million in cash and investments as of June 30, 2025, with a net loss of $9.1 million for Q2 2025.
Additionally, positive preclinical results showed NVG-291-R's efficacy in treating traumatic hearing loss and peripheral nerve injury in U.S. Department of Defense sponsored studies. The company is now pursuing expedited FDA approval pathways for NVG-291.